ZILRETTA decreased peak systemic exposure

18x lower peak plasma concentration with ZILRETTA

Reduced peak systemic exposure to triamcinolone acetonide (TA) (1144 pg/mL) compared to TAcs (21,062 pg/mL)*

Joint residence time chart
  • Results based on a study evaluating concentration of TA in plasma following a single intra-articular injection of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) (n=60) or TAcs (n=18)2
    • ZILRETTA: Blood samples were collected periodically over 24 hours and at Weeks 1, 6, 12, 16, and 20
    • TAcs: Samples were collected periodically over 24 hours and at Week 6
*

Based on Cmax levels following a single intra-articular injection of ZILRETTA and TAcs.

TAcs=triamcinolone acetonide crystalline suspension.

ZILRETTA injection demonstrated minimal effect on blood glucose

In a study evaluating a single dose of ZILRETTA (n=18) or TAcs (n=15) in patients with type 2 diabetes, glucose values were 155.2 mg/dL at baseline (average over 72 hours prior to injection) and 163.4 mg/dL post-injection (average over 72 hours post-dosing)1

ZILRETTA demonstrated a statistically significantly smaller least squares mean (LSM) change in average daily blood glucose compared with TAcs (14.66 vs 33.88, P=0.0452).1

The clinical relevance of this plasma exposure and blood glucose information is unknown